Results 181 to 190 of about 6,141,319 (295)

Extracellular vesicles in pharmacology: Innovations in drug delivery and therapeutic applications in cancer

British Journal of Pharmacology, EarlyView.
Extracellular vesicles (EVs) are a diverse population of membrane nanoparticles secreted by nearly all cell types, playing a key role in intercellular communication by transferring bioactive macromolecular cargo. In cancer, EVs shape both the local tumour microenvironment and distant premetastatic niches.
Evangelia Pantazaka, Georgios Sivvas, Evangelia Papadimitriou, Constantinos M. Mikelis   +3 more
wiley   +1 more source

Dual inhibitors of CDK2 and TRKA kinases: design, synthesis, antiproliferative activity and molecular modeling of novel pyrazolopyrimidine derivatives. [PDF]

RSC Adv
Attia MH, Lasheen DS, Samir N, Taher AT, Abdel-Aziz HA, Abou El Ella DA.   +5 more
europepmc   +1 more source

Proteomic Analysis Reveals AMPKα‐Mediated Antiandrogen Resistance via Ferroptosis Suppression in Prostate Cancer

Cancer Science, EarlyView.
Antiandrogen‐resistant prostate cancer cells acquire ferroptosis resistance through AMPKα activation and upregulation of ferroptosis suppressor pathways. This adaptive state creates a therapeutic vulnerability, as GPX4 inhibition, particularly in combination with AMPKα inhibition, effectively suppresses the growth of resistant cells.
Masaki Shiota, Tokiyoshi Tanegashima, Takahiko Hajime, Miho Ushijima, Shigehiro Tsukahara, Shohei Nagakawa, Satoshi Kobayashi, Takashi Matsumoto, Masatoshi Eto   +8 more
wiley   +1 more source

Synthesis and Antiproliferative Activity of Fluorinated <i>N</i>-Acetylmannosamine Analogs. [PDF]

J Org Chem
Krčil A, Šutvajová L, Hamala V, Císařová I, Kurfiřt M, Červenková Št'astná L, Bernášková J, Hrstka R, Karban J.   +8 more
europepmc   +1 more source

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

Cancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi, Sakura Hiraide Taniguchi, Yuya Yoshida   +2 more
wiley   +1 more source

Development of Glycoconjugated MAGL Inhibitors with Glucose-Dependent Antiproliferative Activity. [PDF]

Int J Mol Sci
Bononi G, Bertini F, Masoni S, Stefano MD, Mosca R, Felice F, Signore G, Minutolo F, Granchi C, Tuccinardi T, Di Bussolo V.   +10 more
europepmc   +1 more source

Daraxonrasib and Beyond: Pan‐RAS Inhibition, Resistance, and Next‐Generation Strategies

Cancer Science, EarlyView.
ABSTRACT RAS proteins have long been considered difficult therapeutic targets, but allele‐selective inhibitors established the clinical tractability of mutant RAS. Daraxonrasib (RMC‐6236), an oral pan‐RAS inhibitor, has now extended this concept by targeting multiple mutant and wild‐type RAS proteins.
Ryo Honda
wiley   +1 more source

Development of Amorphous Solid Dispersion to Improve the Dissolution and Antiproliferative Activity of Brazilin. [PDF]

Drug Des Devel Ther
Tristiyanti D, Sriwidodo S, Hamdani S, Daruwati I, Budiman A.   +4 more
europepmc   +1 more source

Dietary Leucine Restriction Suppresses Platelet‐Driven HCC Growth by Attenuating mTOR Signaling

Cancer Science, EarlyView.
Platelets induce leucine accumulation in HCC cells. In vitro, leucine deprivation or S6K1 inhibition with PF‐4708671 suppresses platelet‐promoted proliferation, migration, and invasion. In vivo, dietary leucine restriction reduces tumor growth following platelet pre‐incubation.
Xeulian Ruan, Guiyong Ou, Cuiju Mo, Yi Zhang, Shanzi Qin, Yongling Chen, Dan Li, Liuying Nie, Li Xie, Zuojian Hu   +9 more
wiley   +1 more source

TRIM32 controls timely cell cycle exit in muscular differentiation through downregulation of c‐Myc mRNA

The FEBS Journal, EarlyView.
Trim32 regulates the transition from proliferation to differentiation in C2C12 cells after myogenic induction. We found that, at the onset of differentiation, Trim32 destabilizes c‐Myc mRNA, promotes cell cycle exit, and enables normal myotube formation.
Lu Xiong, Elisa Lazzari, Sabrina Pacor, Simeone Dal Monego, Erica Piovesan, Danilo Licastro, Germana Meroni   +6 more
wiley   +1 more source